9.74

0.71% -0.07

Biocryst Pharmaceuticals Inc (BCRX)

Overview News Price History Option Chain Financials Why BCRX Down? Discussions Forecast

Biocryst Pharmaceuticals Inc stock is traded at $9.74, with a volume of 3.82M. It is down -0.71% in the last 24 hours and up +0.00% over the past month. BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Previous Close:

$9.81

Open:

$9.68

24h Volume:

3.82M

Relative Volume:

0.80

Market Cap:

$2.49B

Revenue:

$885.72M

Net Income/Loss:

$-457.98M

P/E Ratio:

-5.4827

EPS:

-1.7765

Net Cash Flow:

$293.05M

1W Performance:

+3.84%

1M Performance:

+0.00%

6M Performance:

+44.08%

1Y Performance:

+15.27%

1-Day Range:

$9.46

$9.7999

1-Week Range:

$9.2801

$10.68

52-Week Range:

$6.00

$11.22

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name

Biocryst Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

919-859-1302

Address

4505 EMPEROR BOULEVARD, DURHAM, NC

Employee

435

Twitter

@biocrystpharma

Next Earnings Date

2026-08-05

Latest SEC Filings

BCRX's Discussions on Twitter

Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCRX Biocryst Pharmaceuticals Inc	9.74	2.71B	885.72M	-457.98M	293.05M	-1.7765
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-26	Resumed	Evercore ISI	Outperform
Oct-15-25	Resumed	TD Cowen	Buy
Oct-01-25	Downgrade	Evercore ISI	Outperform → In-line
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Feb-25-25	Initiated	Wedbush	Outperform
Nov-20-23	Resumed	JP Morgan	Overweight
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-04-23	Upgrade	Jefferies	Hold → Buy
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy
Feb-22-23	Upgrade	Needham	Hold → Buy
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Dec-10-21	Initiated	Oppenheimer	Outperform
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight
Mar-01-21	Initiated	Cowen	Outperform
Sep-29-20	Resumed	JP Morgan	Overweight
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy
May-24-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-16-18	Resumed	Piper Jaffray	Overweight
Aug-08-18	Resumed	JP Morgan	Overweight
Jul-17-18	Upgrade	BofA/Merrill	Underperform → Neutral
Jun-22-18	Initiated	Seaport Global Securities	Neutral
Jan-02-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-20-17	Initiated	Barclays	Equal Weight
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Sep-06-17	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-17	Upgrade	Jefferies	Hold → Buy
Feb-16-17	Initiated	Ladenburg Thalmann	Buy
Aug-12-16	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-04-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	FBR Capital	Outperform
Feb-09-16	Downgrade	JP Morgan	Overweight → Neutral
Feb-09-16	Downgrade	Needham	Buy → Hold

View All

Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News

01:32 AM

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st

01:32 AM

Aug 14, 2026

Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Aug 14, 2026

Aug 13, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - MarketBeat

Aug 13, 2026

Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance

Aug 13, 2026

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance

Aug 13, 2026

Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Aug 13, 2026

Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Aug 13, 2026

Aug 12, 2026

BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 12, 2026

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance

Aug 12, 2026

Aug 11, 2026

A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus

Aug 11, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - MarketBeat

Aug 11, 2026

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options - Yahoo Finance

Aug 11, 2026

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? - Yahoo Finance

Aug 11, 2026